

DEPARTMENT OF NEONATOLOGY

Dr Alison Bedford-Russell
Dr Gemma Holder
Dr Andy Ewer
Dr Rob Negrine
Dr Anju Singh

Dr Vel Ramalingam
Dr Vishna Rasiah
Dr Amrit Dhillon (Transport)
Dr Debbie Derbyshire
Dr Manobi Borooh

Mindelsohn Way
Edgbaston
Birmingham B15 2TG
0121 472 1377

Medical Secretaries (based in Norton Court)

Kim.Homer@bwhct.nhs.uk

Tel: 0121-627 2689

Neonatal Medical Secretaries Fax: 0121-627 2749

Laura.Streek@bwhct.nhs.uk

Tel: 0121-623 6893

PLEASE QUOTE BIRMINGHAM WOMEN'S HOSPITAL REGISTRATION NUMBER ON ALL COMMUNICATIONS

GP Letter

Centre Number (if applicable): xxx

Patient Study Number: xxx

Date and version: 28 July 2010, V1.0

Acronym and title of study: PlaNet-2 Platelets for Neonatal Transfusion Study

Randomised Controlled Trial

ISRCTN:

Dear Dr _____

Your patient, _____ (date of birth dd/mmm/yyyy), has been entered into the above trial.

I am writing to inform you that the above baby was enrolled into a clinical study during their recent stay in the neonatal unit (NICU). The purpose of the study is to find out at what level of platelet count we should give platelet transfusions in babies with thrombocytopaenia who are not bleeding. Currently we have no clear understanding of the level of platelet count which should be used to decide when to give platelet transfusions to babies. It is also not clear whether these transfusions are always necessary, especially knowing that all transfusions carry a degree of risk.

The baby is no longer actively participating in the study, as they have been discharged home, but there will be a follow up at two years.

The follow up part of the study involves collecting data about the child's development at a corrected age of 2 years. This is common in many large neonatal trials. We will be contacting the paediatricians, neonatologists, parents/guardians at that time, to complete a short assessment of their development.

Please find enclosed a copy of the parent information sheet for this trial.

Yours sincerely

Dr Manobi Borooh
Consultant Neonatologist (Local Principal Investigator)